About: http://data.cimple.eu/news-article/49161e8ceb5465d742ff36e995842e41b96af035f894d22d13249067

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/49161e8ceb5465d742ff36e995842e41b96af035f894d22d13249067 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	US President Joe Biden plans to announce an arrangement for pharma giant Merck to produce Johnson & Johnson's single-dose Covid-19 vaccine to boost supply, a senior Biden administration told AFP Tuesday. The official confirmed a Washington Post report on the unusual agreement, which is designed to significantly boost vaccine supply as the Biden administration seeks to tame a coronavirus outbreak that has claimed more than 500,000 American lives. The J&J vaccine is the third to receive US regulatory approval for emergency use, but the first that requires a single shot as opposed to two jabs. Merck will dedicate two facilities in the United States to the J&J vaccine build-out, one to manufacture the vaccine and the other to conclude the production process by putting the substance in vials and packing it for shipment, the Post reported. Neither Merck nor J&J immediately responded to a request for comment. The Food and Drug Administration's greenlighting of the J&J vaccine follows December provisional approvals of those by Pfizer and Moderna. The J&J shot appears less protective than Pfizer and Moderna's regimes, which both have an efficacy of around 95 percent against all forms of Covid-19 from the classic coronavirus strain. All three have been shown to fully protect against hospitalizations and death, however. J&J has said it aims to deliver 20 million doses by the end of March, with 100 million by June -- though the US is pushing to expedite that timeline. Prior to approval of the vaccine, White House Coronavirus Response Coordinator Jeff Zients had said the federal government aimed to distribute three to four million doses this week. A major vaccine producer in its own right, Merck had begun work on its own coronavirus vaccines, but abandoned those efforts in January, saying its candidates produced immune responses that were "inferior" to successful Covid-19 vaccines. jmb/hs
schema:headline	Merck to make J&J vaccine to boost supply: US official
schema:mentions	Jeffrey Zients Agence France-Presse Johnson & Johnson Merck Group George Washington White House Pfizer Joe Biden Vaccine United States Coronavirus Severe acute respiratory syndrome coronavirus 2 President of the United States Coronavirus disease 2019
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2021-03-02 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	neutral sentiment
http://data.cimple...readability_score	86 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 11 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software